CD1D and neoplasm: This heightened cytotoxic response suggests that Decitabine-treated tumor cells are more susceptible to Allo15CAR33-NKT cell-mediated killing, likely due to the upregulation of NKR ligands and CD1d on the tumor cells (Fig. 7g).